TimeScale Financial’s Alexion Pharmaceuticals ALXN Stock Holding History

TimeScale Financial’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-36	Closed	-$7K	–	545
2021 Q2	$7K	Buy	+36	New	+$6.18K	﹤0.01%	360
2020 Q3	–	Sell	-214	Closed	-$24K	–	524
2020 Q2	$24K	Buy	+214	New	+$22.7K	0.01%	206

Other funds holding ALXN

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

TimeScale Financial's ALXN Position: Q3 2021 in Review

TimeScale Financial sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 36 shares — an estimated $7K sold.

TimeScale Financial first reported a position in ALXN in Q2 2020 and held it in 2 quarters. The position peaked at $24K in Q2 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

TimeScale Financial reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
TimeScale Financial sold 36 Alexion Pharmaceuticals shares in Q3 2021, an estimated $7K.
TimeScale Financial first reported a position in Alexion Pharmaceuticals in Q2 2020 and held it in 2 quarters.
TimeScale Financial's Alexion Pharmaceuticals position peaked at $24K in Q2 2020.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on TimeScale Financial's 13F filing for Q3 2021, filed 10 Nov 2021.